13833.73
0.03MXN
13.40 BMXN
206.18 BMXN
1.71 B
About ASTELLAS PHARMA
Sector
CEO
Naoki Okamura
Headquarters
Tokyo
Website
Employees (FY)
14.48 K
Founded
1923
ISIN
JP3942400007
FIGI
BBG01255KWM0
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 4503/N is 204.11 MXN — it has decreased by 22.64% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange ASTELLAS PHARMA stocks are traded under the ticker 4503/N.
ASTELLAS PHARMA is going to release the next earnings report on Apr 25, 2024. Keep track of upcoming events with our Earnings Calendar.
4503/N stock is 29.27% volatile and has beta coefficient of 0.65. Check out the list of the most volatile stocks — is ASTELLAS PHARMA there?
One year price forecast for ASTELLAS PHARMA has a max estimate of 275.91 MXN and a min estimate of 165.55 MXN.
4503/N earnings for the last quarter are −0.09 MXN whereas the estimation was 2.98 MXN which accounts for −103.13% surprise. Estimated earnings for the next quarter are 2.02 MXN. See more details about ASTELLAS PHARMA earnings.
ASTELLAS PHARMA revenue for the last quarter amounts to 45.74 B MXN despite the estimated figure of 41.40 B MXN. In the next quarter revenue is expected to reach 46.62 B MXN.
Yes, you can track ASTELLAS PHARMA financials in yearly and quarterly reports right on TradingView.
4503/N net income for the last quarter is 1.75 B MXN, while the quarter before that showed −170.19 M MXN of net income which accounts for 1.13 K% change. Track more ASTELLAS PHARMA financial stats to get the full picture.
Today ASTELLAS PHARMA has the market capitalization of 289.09 B, it has decreased by 1.01% over the last week.
ASTELLAS PHARMA dividend yield was 3.19% in 2022, and payout ratio reached 110.62%. The year before the numbers were 2.62% and 74.53% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, 4503/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ASTELLAS PHARMA stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 14.48 K employees. See our rating of the largest employees — is ASTELLAS PHARMA on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ASTELLAS PHARMA technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ASTELLAS PHARMA stock shows the strong sell signal. See more of ASTELLAS PHARMA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on ASTELLAS PHARMA future price: according to them, 4503/N price has a max estimate of 275.91 MXN and a min estimate of 165.55 MXN. Read a more detailed ASTELLAS PHARMA forecast: see what analysts think of ASTELLAS PHARMA and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ASTELLAS PHARMA EBITDA is 39.23 B MXN, and current EBITDA margin is 25.76%. See more stats in ASTELLAS PHARMA financial statements.